HR Execs on the Move

Contract Pharmaceuticals Limited

www.cplltd.com

 
CPL is a leading contract development and manufacturing organization (CDMO) that provides development, manufacturing, packaging, and testing of non-sterile liquid and semi-solid pharmaceutical and regulated OTC products.
  • Number of Employees: 250-1000
  • Annual Revenue: $500M-1 Billion
  • www.cplltd.com
  • 7600 Danbro Crescent
    Mississauga, ON CAN L5N 6L6
  • Phone: 905.821.7600

Executives

Name Title Contact Details

Similar Companies

Alliance Health Networks

Alliance Health Networks is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Paragon Laboratories

Paragon Laboratories is a Torrance, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ohm Laboratories

Ohm Laboratories is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

True Health

True Health (formerly Central Florida Family Health Center) is a non-profit patient-centered medical home that has been serving the Central Florida community since 1977. Our centers, conveniently located throughout Central Florida, aim to bring you ...

Ripple Therapeutics

The Ripple Therapeutics Epidel® technology is founded on a discovery that drugs can be engineered into controlled release materials without the use of polymers or excipients. The proprietary prodrugs are new chemical entities (NCEs) that have unique properties that allow them to be processed into standalone drug delivery implants (e.g. intravitreal implants, micro/nanoparticles, etc.) or as coatings on medical devices. Ripple Therapeutics implants and coatings are made up entirely from the prodrug without a polymeric carrier to control the implant or drug release properties. The implants and coatings undergo surface erosion to give zero order drug release profiles and are highly engineerable (e.g. different forms, shapes, and sizes) to tailor drug dose and duration for the specific indication of interest. The flexibility in molecular design results in drug doses that are within the therapeutic window, delivering the right amount of drug for the right amount of time. This has the potential to improve patient safety and clinical outcomes.